ESR1 and breast carcinoma: To address this, we developed a fluorescent analog of the drug tamoxifen with specific binding affinity for estrogen receptor-positive (ER+) breast cancer cells, achieved using a BODIPY®FL fluorophore conjugate and a hydrophilic linker.24